Abstracts tagged "macrophage activation syndrome"

Abstract Number: 2199 • 2014 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients
Bertrand Dunogué¹, Magdalena Gerin², Claire Larroche³, Catherine Montagnier-Petrissans⁴, Loïc Guillevin⁵ and Luc Mouthon⁵, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Internal Medicine, Hôpital Jean Verdier, Bondy, France, ³Internal Medicine, Hôpital Avicenne, Bobigny, France, ⁴Groupe d'Expert AP-HP, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Intravenous Immunoglobulins (IVIg) have been reported as giving good results in infectious, but also auto-immune related forms of hemophagocytic lymphohistiocytosis (HLH), but only in…
Abstract Number: 2200 • 2014 ACR/ARHP Annual Meeting
Elevated Serum Ferritin Levels in Adult Inpatients As a Predictor of in-Hospital Mortality and Association with Macrophage Activation Syndrome
Matthew Mullen¹, Marcin Trojanowski², W. Winn Chatham³ and Bita Shakoory³, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Medicine/ Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Macrophage Activation Syndrome (MAS) is a syndrome similar to Familial Hemophagocytic Lymphohistiocytosis (HLH) characterized by increased proliferation and activity of T-cells and macrophages leading…
Abstract Number: 1243 • 2014 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Complicating Adult Onset Still’s Disease – Single Center Experience and Literature Review
Aleksander Lenert¹ and Qingping Yao², ¹Orthopaedic and Rheumatologic Institute, Dept. of Rheumatic & Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening complication typically associated with hematologic malignancies and infections. HLH, also referred to as macrophage activation syndrome (MAS),…
Abstract Number: 2017 • 2013 ACR/ARHP Annual Meeting
Hyper Ferritinemia Suggests a High Frequency Of Macrophage Activation Syndrome In a Large Adult Severe Sepsis Cohort: A Role For Anakinra?
Bita Shakoory¹, Joseph A. Carcillo² and Steven Opal³, ¹Medicine/Rheumatology, Temple University, Philadelphia, PA, ²Pediatrics, University of Pittsburg Medical Center, Pittsburgh, PA, ³Medicine, Brown University, Providence, RI
Background/Purpose: Inreased ferritin levels are protective during infection whereas but very very high level are associated with MAS in rheumatologic disease cTo determine frequency of…
Abstract Number: 2018 • 2013 ACR/ARHP Annual Meeting
Hemophagocytic Lymphohistiocytosis As a Clinical Syndrome Of Autoimmune Diseases, Haematology, Oncology and Infectious Diseases
César Antonio Egües Dubuc, Vicente Aldasoro Cáceres, Miren Uriarte Ecenarro, Carlos Meneses Villalba, Nerea Errazquin Aguirre, Iñaki Hernando Rubio, Olga Maiz Alonso, Jorge Cancio Fanlo, Esther Uriarte Isacelaya and Joaquin Belzunegui Otano, Rheumatology, Donostia University Hospital, San Sebastián, Spain
Background/Purpose :Hemophagocytic Lymphohistiocytosis (HLH) is a severe and acute inflammatory syndrome usually fatal without treatment. HLH includes a spectrum of diseases produced by the proliferation and activation of…
Abstract Number: 79 • 2013 ACR/ARHP Annual Meeting
Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments
Peter L.E.M. van Lent¹, Rik Schelbergen¹, Menno C. ter Huurne², Arjen B. Blom¹, Johannes Roth³, Thomas Vogl⁴, Christian Jorgensen⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁶Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: A substantial subpopulation of patients with early osteoarthritis (OA) show a thickened synovial lining layer comprising macrophages expressing an activated phenotype (reflected by production of…
Abstract Number: 2525 • 2012 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Linda M. Hartkamp¹, Inge E. van Es¹, Jay S. Fine², Michael Smith², John Woods², Satwant Narula³, Julie DeMartino², Paul P. Tak⁴ and Kris A. Reedquist¹, ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, ³Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and progressive autoinflammatory disorder characterized by the infiltration of inflammatory cells, including B-cells, T-cells and macrophages, in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].